Acceleron in advanced talks for $11B sale
Buyer unknown, but several drugmakers -- including Bristol-Myers Squibb Co., owners of 11.5% of Acceleron stock -- seen as potential suitors
Check out what's clicking on FoxBusiness.com.
U.S. drugmaker Acceleron Pharma Inc is in advanced talks to be acquired by a large pharmaceutical company for more than $11 billion, Bloomberg News reported on Friday, citing people familiar with the matter.
The acquisition would be made at about $180 per share in cash, the report said.
COVID VACCINE MANUFACTURER TAKING 'GO FORWARD' APPROACH TO SHOTS
Details about the potential buyer were not known, but the report added that several global drugmakers, including Bristol-Myers Squibb Co, which owns 11.5% of Acceleron's stock, are seen as potential suitors.
In this photo illustration an Acceleron Pharma logo of a biopharmaceutical company is seen on a smartphone screen. The U.S. drugmaker is reportedly in advanced talks to be acquired by a large pharmaceutical company for more than $11 billion, Bloomber …
Acceleron did not immediately respond to Reuters' request for comment.
CLICK HERE TO READ MORE ON FOX BUSINESS
Acceleron, based in Cambridge, Massachusetts is a clinical-stage biopharmaceutical company with a total market value of $10.2 billion. The company focuses on the discovery, development and commercialization of therapeutics to treat serious and rare diseases